

Business Management Information

If you need further information after reviewing the contents of the document business management assistance may be obtained from Lisa T. Garbarino, Grants Management Specialist, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Mailstop E-13, Atlanta, GA 30305, telephone (404) 842-6796 or internet: lgt1@cdc.gov

Programmatic Technical Information

If you have programmatic questions assistance may be obtained from Ted Jones, Program Manager, Extramural Research Grants Branch, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (CDC), Mailstop K-58, 4770 Buford Highway, NE., Atlanta, Georgia 30341-3724, telephone (770)488-4824 or internet: tmj1@cdc.gov

CDC will not send application kits by facsimile or express mail.

Please refer to Announcement Number 98029 when requesting information and submitting an application.

Potential applicants may obtain a copy of Healthy People 2000 (Full Report, Stock No. 017-001-00474-0) or Healthy People 2000 (Summary Report, Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC, 20402-9325, telephone (202) 512-1800.

Information for obtaining the suggested readings, Violence and the Public's Health, Understanding and Preventing Violence, and Violence in America: A Public Health Approach, is included at the end of the announcement with the application kit.

Application instructions for certificates of confidentiality can be obtained by contacting Betsey Dunaway, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC), Mailstop E-11, 1600 Clifton Rd., NE., Atlanta, Georgia, 30333.

Telephone: 404/639-2942, Internet: BAS1@CDC.GOV

Dated: February 25, 1998.

Joseph R. Carter,

Acting Associate Director for Management And Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-5388 Filed 3-2-98; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Centers for Disease Control and Prevention****National Occupational Research Agenda (NORA) Musculoskeletal Team Focus Group Meeting**

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: National Occupational Research Agenda (NORA) Musculoskeletal Team Focus Group Meeting.

Time and Date: 9 a.m.-3 p.m., March 25, 1998.

Place: Clarion Hotel at O'Hare International, 6810B North Mannheim Road, Rosemont, Illinois 60018, telephone 847/297-8464.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people.

Purpose: The NORA Musculoskeletal Committee is hosting a series of meetings to gather information, from a large array of partners, regarding important needs and issues with respect to prevention of musculoskeletal disorders in industry. These meetings will use focus groups to elicit areas of concern as expressed by representatives of various industry sectors. The present meeting will address the following industry sectors: Heavy manufacturing, light manufacturing, transportation/warehousing, agriculture/food processing, office ergonomics, and health care.

The Committee will share with each specific sector a series of questions helpful in identifying potential research needs. Each sector will develop their own list of research needs. After the three regional meetings are completed, the NORA Musculoskeletal Team will combine the research needs into a consolidated list. The researchers will be asked to identify research activities which can address research needs identified by the regional meetings. A separate meeting of musculoskeletal researchers is proposed for summer 1998.

The goal of these meetings is to develop a research agenda that reflects the needs and information gaps identified by individuals who confront musculoskeletal disorders frequently, including managers, workers, industry, unions, and clinicians. Output from the meeting will consist of a research agenda for each industry, as well as transcripts. Meetings will be audio taped to develop the transcript of the meeting, and to describe the process as well as the final outcome. Once the research agenda has been established, work will begin on the implementation process.

The ultimate goal of this process is to expand and deepen the partnership concept that is fundamental to the NORA process, and to develop a research agenda that is responsive to the needs of NIOSH partners in business, labor, academia, and government with respect to the control of musculoskeletal

disorders. The goal is reflected in the motto of the NORA Musculoskeletal Committee: "Promote Health and Reduce Lost Work Time."

Contact Person for Additional Information: Sean Gallagher, NIOSH, CDC, Pittsburgh Research Laboratory, PO Box 18070, Pittsburgh, Pennsylvania 15236-0070, telephone 412/892-6445, e-mail address: sfg9@cdc.gov.

Dated: February 25, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98-5386 Filed 3-2-98; 8:45 am]

BILLING CODE 4160-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration****Arthritis Advisory Committee; Notice of Meeting**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Arthritis Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on March 24 and 25, 1998, 8 a.m. to 5 p.m.

Location: Holiday Inn Gaithersburg, Walker and Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Kathleen R. Reedy or LaNise S. Giles, Center for Drug Evaluation and Research, (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12532. Please call the Information Line for up-to-date information on this meeting.

Agenda: On March 24, 1998, the committee will discuss safety issues, gastrointestinal tolerability, renal, bone and reproductive toxicity related to nonsteroidal anti-inflammatory drugs, for example, COX-2 and other agents. On March 25, 1998, the committee will discuss the pain claim structure for chronic and acute pain and onset of pain relief including appropriate study